Latest & greatest articles for colon cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colon cancer screening

1. Colon cancer screening

for Disease Control and Prevention (CDC's) Screen for Life materials. Some participants also will be asked to read a personal narrative about colon cancer screening . This study will determine whether participant's perceptions about 2015 16. Colon Capsule to Screen for Colorectal Neoplasia in Subjects with a Family History of Colorectal Cancer . BACKGROUND AND AIMS: Colon capsule endoscopy (CCE) has been recognized as an alternative for colorectal cancer (CRC) screening in average risk subjects (...) administration is a key factor in the tolerability and efficacy of colon preparation in colorectal cancer screening ]. 236-42 10.1016/j.gastrohep.2012.01.012 The quality and tolerability of antegrade (...) gut lavage bowel preparation are key elements in the success of population-based colorectal cancer screening . To evaluate cleansing quality and tolerability according to the timing of polyethylene glycol administration in persons undergoing colorectal cancer screening . Participants in colorectal cancer

2018 Trip Latest and Greatest

2. Colorectal Cancer Screening

E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal- cancer screening. N Engl J Med. 2012 Feb 23; 366(8):697-706. Redwood DG, Asay ED, Blake ID et al. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc. 2016 Jan; 91(1):61-70. Rosty C, Hewett DG, Brown IS, Leggett BA, Whitehall VL. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J (...) deaths in the United States. There is good evidence that CRC-related morbidity and mortality can be reduced through early detection and treatment of early-stage disease and through the identification and removal of adenomas, the precursor of colorectal cancers. Definitions: Neoplastic Colorectal Polyps and Adenomas Adenomatous polyps (also called adenomas) are growths with malignant potential, and are the most common type of colorectal polyp. Adenomatous polyps may be pathologically classified

2017 Kaiser Permanente Clinical Guidelines

3. Blood and stool biomarker for colorectal cancer screening

screening in Australia, however, due to the rapidly evolving evidence base around a number of these tests, HealthPACT recommended that this technology be reassessed in 24 months. Description of the technology Bowel cancer, which includes cancers of the colon, recto-sigmoid junction and rectum, is a major cause of morbidity and mortality in Australia. Although colonoscopy is the gold standard for the detection of colorectal cancer (CRC), it is expensive, and by virtue of its invasive nature, associated (...) generation FOBT - an automated immunochemical faecal occult blood test (iFOBT). 4 Faecal occult blood testing looks for minute traces of haemoglobin in stool samples, which may be a result of upper or lower gastrointestinal bleeding potentially caused by not only benign or malignant growths or polyps of the colon, but many conditions including: inflammatory bowel disease, haemorrhoids, ulcerative colitis or Crohn’s disease. The gFOBT uses hydrogen peroxide, which in the presence of blood results

2016 COAG Health Council - Horizon Scanning Technology Briefs

4. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Have inflammatory bowel disease Have hereditary syndromes that increase the risk of colorectal cancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectal cancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowel cancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer

2019 BMJ Rapid Recommendations

5. Recommendations on screening for colorectal cancer in primary care

of colorectal cancer in 2015 (incidence 49 per 100 000 population) and that 9300 will die from the disease (mortality 17 per 100 000). 1 The incidence and mortality of colorectal cancer are low until middle age and rise rapidly there- after (Figure 1). 1,4 Most colorectal cancers appear to arise from colonic polyps that develop slowly and some- times transform to cancers. 5 This is the ration ale for screening programs that aim to reduce deaths due to colorectal cancer by detecting and remov- ing polyps (...) as a screening test for colorectal cancer. (Weak recommendation; low-quality evidence) These recommendations apply to adults aged 50 years and older who are not at high risk for colorectal cancer. They do not apply to those with previous colorectal cancer or polyps, inflammatory bowel disease, signs or symptoms of colorectal cancer, history of colorectal cancer in one or more first-degree relatives, or adults with hereditary syndromes predisposing to colorectal cancer (e.g., familial adenomatous polyposis

2016 CPG Infobase

6. Screening for Colorectal Cancer

of CRC or advanced adenoma warrants more intense screening for CRC. Well-designed prospective studies are needed in order to make de?nitive evidence-based recommendations about the age to commence screening and appropriate interval between screening tests. Keywords: Adenoma; Cancer; Colonoscopy; Colorectal; FOBT; Neoplasms; Polyp; Screening. Executive Summary Colorectal cancer (CRC) is the second leading cause of cancer deaths in Canada and the United States. A positive family history (FH) signi (...) with papillary thyroid cancer that is the cribriform-morular variant, or hepatoblastoma Individuals with a diagnosis of CRC and>10 colorectal adenomas Individuals with a personal history of20 adenomas Individuals with multiple gastrointestinal hamartomatous polyps or serrated polyposis syndrome Individuals from a family with a known hereditary syndrome associated with CRC with or without a known mutation Individuals with a desmoid tumor, multifocal or bilateral CHRPE CHRPE, congenital hypertrophy of retinal

2018 Canadian Association of Gastroenterology

7. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer 2

) is a panel of expert gastroenterologists representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. Th e MSTF, like others, has long endorsed systematic off ers of CRC screening to average-risk persons (persons without a high-risk family history of colorectal neoplasia) beginning at age 50 years, with general evidence supporting screening reviewed in previous publications ( 1 ). Th is publication updates (...) cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The ? rst-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT

2017 American College of Gastroenterology

8. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Full Text available with Trip Pro

-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Diseases of the Colon and Rectum 2011; 54(7): 876-886 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Colonoscopy /economics; Colorectal Neoplasms /diagnosis /economics /epidemiology; Cost-Benefit Analysis; Female; France /epidemiology; Guaiac /economics; Guidelines as Topic; Humans; Immunologic Tests /economics /methods; Incidence; Indicators (...) Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I Record Status This is a critical abstract of an economic evaluation that meets

2012 NHS Economic Evaluation Database.

10. Colorectal Cancer Screening

35% of polyps 6 to 10 mm and 17% of polyps >11 mm [58]. A retrospective study evaluated the diagnostic yield of DCBE examinations performed for colorectal cancer screening in average-risk individuals >50 years of age [59]. The diagnostic yield was 5.1% for neoplastic lesions =10 mm and 6.2% for advanced neoplastic lesions, regardless of size. These diagnostic yields fall within the lower range of those reported for screening colonoscopy (5.0% to 9.5% for colonic neoplasms =10 mm [60-62] and 4.6 (...) % and specificity ranged from 87% to 99%. For advanced neoplasia =6 mm, per- patient sensitivity was 89% and specificity ranged from 97% to 99% [89]. In a study of 24 patients who presented with rectal bleeding, a positive FOBT, or altered bowel habits, MR colonography with barium-based fecal tagging detected all polyps >8 mm [90]. A tap water enema was used to distend the colon, and intravenous contrast material was administered [90]. Variant 4: Colorectal cancer screening. High-risk individual. Hereditary

2018 American College of Radiology

11. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer

the blood vessel pattern (and the histologic features) of an adenoma. The white arrows point to non-dysplastic portions of this sessile serrated polyp. ( F ), A sessile serrated polyp with invasive cancer; white arrows designate the residual sessile serrated polyp, whereas yellow arrows indicate the ulcerated malignant portion of the lesion. This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents (...) Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Volume 153, Issue 1, Pages 307–323 To read this article in full, please review your options for gaining access

2017 American Gastroenterological Association Institute

12. Screening for Colorectal Cancer*

be substantial. As such, the benefit of early detection of and intervention for colorectal cancer in adults 86 years and older is at most small. To date, no method of screening for colorectal cancer has been shown to reduce all-cause mortality in any age group. Harms CTFPHC (2016) False-positive and false-negative results were the only direct harms reported for gFOBT and FIT in the included studies. Harms following FS were rare (intestinal perforation occurred in 0.001% of patients, minor bleeding in 0.05 (...) Screening for Colorectal Cancer* Screening for Colorectal Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Jan 2017 - 14 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has

2016 National Guideline Clearinghouse (partial archive)

13. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. Mailed fecal immunochemical test (FIT) outreach is more effective than colonoscopy outreach for increasing 1-time colorectal cancer (CRC) screening, but long-term effectiveness may need repeat testing and timely follow-up for abnormal results.Compare the effectiveness of FIT outreach and colonoscopy outreach to increase completion of the CRC screening (...) for individuals in the FIT outreach group with normal results and completion of diagnostic and screening colonoscopy for those with an abnormal FIT result or assigned to colonoscopy outreach.Primary outcome was screening process completion, defined as adherence to colonoscopy completion, annual testing for a normal FIT result, diagnostic colonoscopy for an abnormal FIT result, or treatment evaluation if CRC was detected. Secondary outcomes included detection of any adenoma or advanced neoplasia (including CRC

2017 JAMA Controlled trial quality: predicted high

14. Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: The importance of cancer prevention in addition to cancer detection Full Text available with Trip Pro

Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: The importance of cancer prevention in addition to cancer detection Colorectal cancer (CRC) screening can be undertaken utilizing a variety of distinct approaches, which provides both opportunities and confusion. Traditionally, there has often been a trade-off between the degree of invasiveness of a screening test and its ability to prevent cancer, with fecal occult blood testing (FOBT) and optical (...) colonoscopy (OC) at each end of the spectrum. CT colonography (CTC), although currently underutilized for CRC screening, represents an exception since it is only minimally invasive, yet provides accurate evaluation for advanced adenomas. More recently, the FDA approved a multi-target stool DNA test (Cologuard) and a blood-based test (Epi proColon) for average-risk CRC screening. This commentary will provide an overview of these two new non-invasive tests, including the clinical indications, mechanism

2016 Abdominal radiology (New York)

15. Colorectal Cancer Screening (PDQ®): Health Professional Version

blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (19): 1365-71, 1993. [ ] Hewitson P, Glasziou P, Watson E, et al.: Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103 (6): 1541-9, 2008. [ ] Description of the Evidence Incidence and Mortality Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide [ ] and the third leading cause of cancer deaths in the United States (...) sponsored by an employer), 5.6% had advanced neoplasms.[ ] Forty-six percent of those with advanced proximal neoplasms had no distal polyps (hyperplastic or adenomatous). If colonoscopy screening is performed only in patients with distal polyps, about half the cases of advanced proximal neoplasia will not be detected. A study of colonoscopy in women compared the yield of sigmoidoscopy versus colonoscopy. Of the 1,463 women, cancer was found in 1 woman and advanced colonic neoplasia was found in 72 women

2017 PDQ - NCI's Comprehensive Cancer Database

16. Colorectal Cancer Screening Evidence Brief

with a personal or family history of colorectal cancer or adenomatous polyps, persons with inflammatory bowel disease, and those with symptoms that may be attributable to colorectal. Background Recently, the American Cancer Society (ACS) released their updated 2018 Colorectal Cancer (CRC) Screening Guidelines. These guidelines added the qualified recommendation* that screening for average risk patients start at 45 years of age regardless of race. Screening all adults aged 50 years and older, which (...) fruits and vegetables, fiber, and calcium). Awareness Given the data that colorectal cancer is increasing in younger individuals we must be more vigilant for signs and symptoms that could indicate a problem. I want to know if you develop blood in your stools, anemia, abdominal pain, or changes in bowel habits. However, it is also important to realize that early colon cancers and precancerous polyps do not commonly cause symptoms. 5 References American Academy of Family Physicians Statement: https

2019 Institute for Clinical Systems Improvement

17. Cost-effectiveness study: Colorectal cancer screening is cost-effective in the elderly who have had less intense prior screening, high baseline risk of colorectal cancer and less comorbidities

screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness . . Context Eligibility for colorectal cancer screening programmes is usually age-based from 50 to 74 years; the sector of the population in which most disease occurs and, on average, the sector standing to gain most from prevention/early detection. However, given colorectal cancer risk is affected by many factors, a wide spectrum of colorectal cancer risk exists meaning (...) Cost-effectiveness study: Colorectal cancer screening is cost-effective in the elderly who have had less intense prior screening, high baseline risk of colorectal cancer and less comorbidities Colorectal cancer screening is cost-effective in the elderly who have had less intense prior screening, high baseline risk of colorectal cancer and less comorbidities | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your

2016 Evidence-Based Medicine

18. Colon Cancer Screening with Colonoscopy

Colon Cancer Screening with Colonoscopy Colon Cancer Screening with Colonoscopy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Colon (...) ) Colonoscopy is a procedure that lets your doctor look inside your entire large intestine. It uses an instrument called a colonoscope, or scope for short. Scopes have a tiny camera attached to a long, thin tube. The procedure lets your doctor see things such as inflamed tissue, abnormal growths, and ulcers. Your doctor may recommend a colonoscopy: To look for early signs of . It may part of a routine screening, which usually starts at age 50. To look for causes of unexplained changes in bowel habits

2015 FP Notebook

19. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. Full Text available with Trip Pro

Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. 27168447 2016 05 16 2016 05 12 1533-4406 374 19 2016 May 12 The New England journal of medicine N. Engl. J. Med. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. 1898 10.1056/NEJMx150040 eng Published Erratum United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2012 Feb 23;366(8):697-706 22356323 2016 5 12 6 0 2016 5 12 6 0 2016 5 12 6 1 ppublish 27168447 10.1056/NEJMx150040

2016 NEJM